key: cord-0900333-3rpjex22
authors: Renieris, G.; Karakike, E.; Xu, Z.; Gkavogianni, T.; Droggiti, D.- E.; Schubert, K.; Kafousopoulos, D.; Hermann, M.; Netea, M. G.; Eugen-Olsen, J.; Simard, J.; Giamarellos-Bourboulis, E. J.
title: IL-1α Mediates Tissue Specific Inflammation and Severe Respiratory Failure In Covid-19: Clinical And Experimental Evidence
date: 2021-04-15
journal: nan
DOI: 10.1101/2021.04.09.21255190
sha: 43a720e00f1a79bbacc0bc81456140201b06b0d5
doc_id: 900333
cord_uid: 3rpjex22

Background: Acute respiratory distress syndrome (ARDS) in COVID-19 has been associated with dysregulated immune responses leading to catastrophic inflammation. The activation pathways remain to be fully elucidated. We investigated the ability of circulating to induce dysregulated immune responses. Materials & Methods: Calprotectin and high mobility group box 1 (HMGB1) were associated with ARDS in 60 COVID-19 patients. In a second cohort of 40 COVID-19 patients calprotectin at hospital admission was associated with serum levels of soluble urokinase plasminogen activator receptor (suPAR). A COVID-19 animal model was developed by intravenous injection of plasma from healthy volunteers or patients with COVID-19 ARDS into C57/BL6 mice once daily for 3 consecutive days. In separate experiments, mice were treated with a) the IL-1 receptor antagonist Anakinra or vehicle and b) Flo1-2a anti-murine anti-IL-1 monoclonal antibody or the specific anti-human IL-1 antibody XB2001, or isotype controls. Mice were sacrificed on day 4. Cytokines and myeloperoxidase (MPO) in tissues were measured. Results: Calprotectin, but not HMGB1, was elevated ARDS. Higher suPAR readouts indicated higher calprotectin levels. CHallenge of mice with COVID-19 plasma led to inflammatory reactions in murine lung and intestines as evidenced by increased levels of TNF, IL-6, IFN{gamma} and MPO. Anakinra treatment brought these levels down. Similar decrease was found in mice treated with Flo1-2a but not with XB2001. Conclusion: Circulating alarmins, specifically calprotectin, of critically ill COVID-19 patients induces tissue-specific inflammatory responses through an IL-1 mediated mechanism. This could be attenuated through inhibition of IL-1 receptor or specific inhibition of IL-1.

CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 

A little over one year since the onset of the COVID-19 pandemic, more than 79

(https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Despite all 81 efforts to understand the disease, efforts are ongoing to elucidate what drives 82 progression in COVID-19 cases from lower respiratory tract infections (LRTI) to 83 acute respiratory distress syndrome (ARDS). We have suggested that the 84 deterioration from pneumonia to ARDS is the result of a complex immune 85 dysregulation, which in about 25% of patients appears to be related to a macrophage 86 activation like syndrome; while in the remaining 75% of patients the mechanism 87 seems to involve an interleukin (IL)-6 receptor dependent dysregulation, with an 88 associated lymphopenia and a subset of cytokine over-producing monocytes that 89

show decreased human leukocyte antigen (HLA)-DR expression (1). with the recombinant human IL-1 receptor antagonist Anakinra. Anakinra is able to 96 block both IL-1α and IL-1β bioactivity at the level of their common receptor (4) and 97 prevent the development of ARDS. 98

The results of the SAVE trial led us to hypothesise that LRTI caused by 99 SARS-CoV-2 can progress to ARDS. In this hypothesis, as a result of infection by 100 patients were adults of either sex with positive molecular testing of SARS-CoV-2 126 from respiratory secretions and with LRTI defined by the presence of diffuse 127 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 infiltrates by chest X-ray or computed tomography of the chest. Exclusion criteria 128 were a) HIV-1 infection and b) neutropenia defined as less than 1,000 129 neutrophils/mm 3 . Blood was sampled on the day of hospital admission in the 130 emergencies. For patients admitted with ARDS, blood was collected within 24 hours 131 from mechanical ventilation (MV). Control blood samples were collected from healthy 132 volunteers matched for age and gender. 133

The following clinical variables were recorded: i) demographics; ii) severity 134 scores, namely Acute Physiology and Chronic Health Evaluation (APACHE) II score, 135

Charlson's Comorbidity Index (CCI) and Sequential Organ Failure Assessment 136 (SOFA) score; (iii) absolute blood cell counts, biochemistry, and blood gases; (iv) 137 and progression into ARDS during the entire hospital stay. ARDS was defined as a 138 ratio of partial oxygen pressure to fraction of inspired oxygen (PaO 2 / FiO 2 ) below 139 150 mmHg necessitating mechanical ventilation. 140

Five millilitres of whole blood was collected into a tube containing 141 ethylenediaminetetraacetic acid (EDTA) and centrifuged. Calprotectin (S100A8/A9); 142 high-mobility group box 1 (HMGB1); suPAR and ferritin were measured by enzyme-143 linked immunosorbent assays (ELISA) (InflaRx, Jena, Germany and Creative 144 Diagnostics, Shirley, NY, USA; suPARnostic, ViroGates, Lyngby, Denmark and 145 ORGENTEC Diagnostika GmbH, Mainz, Germany, respectively); and C-reactive 146 protein (CRP) was measured using a nephelometric assay (Behring, Berlin, 147 Germany). The lowest limits of detection were: 0.5 ng/ml for HMGB1; 1.1 ng/ml for 148 suPAR; 0.2 mg/l for CRP; and 75 ng/ml for ferritin. RNA isolation of SARS-CoV-149 2 was performed with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). 150

Reverse transcription of the viral RNA into cDNA and enrichment of the sequences 151 of interest via Real-time Polymerase Chain Reaction (PCR) was performed in the 152 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Rotor-Gene Q instrument (Qiagen) using the SARS-CoV-2 reagent Viasure (CerTest 153

Biotec SL, Zaragoza, Spain). 154 155

Animal experiments were conducted in the Unit of Animals for Medical and 157

Scientific purposes of the University General Hospital "Attikon" (Athens, Greece). All 158 experiments were licensed from the Greek veterinary directorate under the protocol 159 number 471955/06-07-2020. 160

We studied 80 male and female C57Bl6 mice (7-8 weeks old). Mice were 161 allowed to acclimate for seven days before beginning of the experiments. They were 162 housed in typical mouse cages, up to 5 mice per cage on 12-h dark/light cycle and 163 allowed free access to standard dry rodent diet and water. Analgesia was achieved 164 with paracetamol suppositories to avoid interactions with the immune system. 165

In order to develop a model of COVID-19-like inflammatory illness, mice were 166 treated intravenously (iv) with 100 μ l of plasma from patients with ARDS due to 167 SARS-CoV-2 infection for 3 consecutive days; control mice were treated with 100 μ l 168 of plasma from healthy volunteers for 3 consecutive days. On the fourth day, mice 169 were sacrificed by subcutaneous (sc) injection of 300 mg/kg ketamine, followed by 170 cervical dislocation. Under sterile conditions a midline abdominal incision was 171 performed. Then, segments of liver, lower lobe of the right lung, right kidney, ileum 172 (ca. 1 cm distally to the pyloric sphincter) and colon (ca. 1 cm proximally of the anal 173 ring) were excised and collected into sterile tubes with 1 ml NaCl 0.9%. The 174

intestinal samples were thoroughly flushed with NaCl 0.9% for removal of feces 175 before storage. The samples were weighed and homogenized. 176 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 Segments of spleens were gently squeezed and passed through a sterile filter 177 (250 mm, 12-13 cm, AlterChem Co, Athens, Greece) for the collection of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.09.21255190 doi: medRxiv preprint they were expressed as MPO units/mg protein/g. 202

Experiments were repeated in mice receiving in addition to i.v. plasma, a) 100 203 μ l sc of 10 mg/kg Anakinra (Swedish Orphan Biovitrum, Stockholm, Sweden) or 100 204 μ l of 0.9% NaCl once daily for 3 days; and b) 100 μ l intraperitoneally (ip) of 1000 205 μ g/ml (12) anti-murine IL-1α antibody Flo1-2a or human IL-1α antibody XB2001, or 206 murine isotype control (XBiotech, TX, USA). 207

In a separate experiment, mice treated with COVID-19 plasma for three days 208

were challenged on the fourth day ip with 1x10 7 cfu/ml E. coli or Acinetobacter 209 baumannii. Survival was recorded every 12 hours for 7 days. 210 211

Categorical data were presented as frequencies and quantitative variables as 213 mean ± SE. Comparisons between groups were done using the Fisher exact test for 214 categorical data. Comparison for quantitative data was performed using the Mann-215 Whitney U test for two group comparisons and the one-way ANOVA with the 216

Bonferroni correction for multiple group comparison. Correlations were performed 217 using the Spearman's rank of order. Any p value below 0.05 was considered 218 statistically significant. 219 220

Forty consecutive patients with COVID-19 who did not develop ARDS during 222 their hospital stay and 20 consecutive patients with ARDS were analyzed. Their 223 demographics are shown in Table 1 . Samples of 10 healthy volunteers were 224 analyzed as healthy controls. Serum calprotectin levels were significantly higher 225 among patients with COVID-19 and ARDS ( Figure 1A ). HMGB1 concentrations did 226 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 not differ between patients with COVID-19 with and without ARDS ( Figure 1B ). 227

calprotectin is released early among patients and may serve as a marker for patients 229 who will progress to ARDS. 230 suPAR was previously identified as an early predictor of ARDS progression in 231 patients with at least 6 ng/ml serum levels in the SAVE trial (3). To study of the early 232 increase of suPAR denotes increases of calcprotectin, calprotectin was measured in 233 40 patients screened for inclusion in SAVE trial. 20 patients were with suPAR 234 concentrations less than 6 ng/ml and 20 patients showed suPAR concentrations ≥ 6 235 ng/ml ( Table 2) . None of the patients with suPAR less than 6 ng/ml developed ARDS; 236 30% of those with suPAR In order to investigate the mechanism by which calprotectin induces the 245 hyperinflammation related to COVID-19 associated respiratory failure, we sought to 246 design a COVID-19 murine model. Mice were challenged with plasma either from 247 healthy volunteers (HV) or from patients with ARDS of COVID-19. Plasma of COVID-248 19 patients led to organ-specific increase of cytokine concentrations. More precisely, 249

TNFα and MPO activity were specifically increased in the lung, ileum and colon of 250 mice challenged with COVID-19 plasma; IL-6 was upregulated in the lung and colon; 251 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 and IFNγ was upregulated in the lung (Figure 2A is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 No correlation was found between Cts and the levels of TNFα, IL-6, IFNγ and MPO in 277 the lung of COVID-19 patients with ARDS due to COVID-19 ( Figure S2 ). This suggests 278 that the hyperinflammation is independent from the viral load. In order to mimic hospital 279 acquired secondary bacterial infections among COVID-19 patients in murine, mice 280 treated for three consecutive days with COVID-19 plasma were further challenged 281 with A. baumannii or E. coli. Survival was significantly lower after challenging with A. 282 baumannii ( Figure 3E ). Observations coming from our prospective cohort of 134 283 ARDS patients revealed higher incidence of secondary infections by A. baumannii 284 when compared to other Gram-negative bacteria (Table S1, Figure S3 ). This further It has been clearly demonstrated that an impaired immune response is a core 297 characteristic of patients who develop ARDS due to SARS-CoV-2 (5). The 298 associated great increase in the mortality of these patients has turned the focus on 299 potential therapeutic targets to disrupt the immune dysregulation. This necessitates a 300 better understanding of the pathogenesis of COVID-19. 301 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 Calprotectin, a heterodimer of S100A8 and S100A9, is a protein secreted by 302 leukocytes. The upregulation of calprotectin expression has been associated with 303 various inflammatory processes such as inflammatory bowel disease, rheumatoid 304 arthritis, spondyloarthritis and cardiovascular disease in type 2 diabetes mellitus (6-305 9). Additionally, calprotectin is crucial for neutrophil accumulation and inflammation 306 in the lung parenchyma during bacterial community acquired pneumonia (10) . 307

Recently, high levels of calprotectin in samples of COVID-19 patients were 308 correlated with disease severity and were associated with increased levels of 309 inflammatory cytokines and chemokines and myelopoiesis of abnormal myeloid cells 310 (11). In this study, we suggest calprotectin as a potential first element in the pathway 311 leading to ARDS in COVID-19 patients. Indeed, we found greater levels in patients 312

with ARDS compared to patients without ARDS. On the contrary, HMGB1, an 313 additional alarmin, which has been associated with sepsis pathogenesis and 314 outcome (12), did not significantly differ among patients with and without ARDS due 315 to COVID-19. Moreover, suPAR which is an early predictor of respiratory 316 deterioration in COVID-19 (3, 13) was indicative of patients with higher calprotectin 317 levels, suggesting that increased suPAR can be the biomarker of DAMP-induced 318 pathways in COVID-19. 319 SARS-CoV-2 uses the cellular surface protein angiotensin-converting enzyme 320 2 (ACE2) to bind and enter cells. However, the mouse ACE2 does not effectively 321 bind the viral spike protein (14). Therefore wild-type mice cannot be directly used as 322 a model to gain insight in COVID-19 pathophysiology. Mice over-expressing ACE2 323 have been used as a strategy to tackle this problem (15). While it is accepted that 324 the interaction of the spike protein of SARS-CoV-2 with human angiotensin 325 converting enzyme 2 (ACE2) is the first step for viral invasion in host cells of the 326 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.09.21255190 doi: medRxiv preprint upper and lower respiratory tract (16), the ability of the virus to directly infect other 327 human tissues, where ACE2 is also expressed, such as the small intestine, kidneys, 328 and the heart, is a matter of dispute (17). In addition, we also need to understand the 329 pure immunological mechanisms of hyperinflammation in COVID-19. This is Our findings provide evidence that progression from LRTI by SARS-CoV-2 to 343 ARDS is a process which is mediated by DAMPs, like IL-1α and calprotectin, 344 released following cell destruction. The early detection of the presence of circulating 345

strategy. This is the hallmark of the efficacy of Anakinra -guided by the biomarker 347 suPAR -which led to a significant decrease in the incidence of ARDS in the SAVE 348 trial (3). 349 350 351 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

In a COVID-like infection model, C57Bl6 mice were challenged intravenously (i.v.) with 516 plasma of healthy volunteers or patients with ARDS due to COVID-19 for three 517 consecutive days. In separate experiments, on each day of plasma challenge, mice 518 were treated with Anakinra, which inhibits human and murine IL-1, or vehicle. Mice were 519 sacrificed on day 4. A-C) Tumor necrosis factor alpha (TNFα); D-E) Interleukin (IL) -6; F) 520

Interferon gamma (IFNγ) and G-I) myeloperoxidase (MPO) activity was determined in 521 tissues. Comparison by the Mann Whitney U test; ns non-significant; p< 0.05; p< 522 0.01. 523 524 525

In a COVID-like infection model, C57Bl6 mice were challenged intravenously (i.v.) with 527 plasma of patients with ARDS due to COVID-19 for three consecutive days. In separate 528 experiments, on each day of plasma challenge, mice were treated with Flo1-2a anti-529 murine IL-1α antibody or XB2001 human IL-1α antibody or murine isotype control 530 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 for Flo1-2a. Mice were sacrificed on day 4. A-C) Tumor necrosis factor alpha (TNFα); 531 D-E) Interleukin (IL) -6; F) Interferon gamma (IFNγ) and G-I) myeloperoxidase (MPO) 532 activity was determined in tissues. Comparison by the Mann Whitney U test; ns non-533 significant; p< 0.05; p< 0.01; p< 0.001. 534 535 536

A-C) In a COVID-like infection model, C57Bl6 mice were treated intravenously (i.v.) with 538 plasma of healthy volunteers or patients with ARDS due to COVID-19 for three 539 consecutive days. Mice were sacrificed on day 4. Splenocytes were isolated and 540 incubated with heat killed C. albicans for the production of interferon-gamma (IFNγ), 541 tumour necrosis factor-alpha (TNFα) and interleukin (IL)-6. 542 D-F) In a COVID-like infection model, C57Bl6 mice were treated intravenously (i.v.) with 543 plasma of patients with ARDS due to COVID-19 with or without treatment with the IL-1 544 receptor inhibitor Anakinra for three consecutive days. 545

Mice were sacrificed on day 4. Splenocytes were isolated and incubated with heat killed 546 C. albicans for the production of IFNγ, TNFα and IL-6. Comparison by the Mann 547 Whitney U test; ns non-significant; p< 0.05; p< 0.01. 548 549 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org /10.1101 /10. /2021 

Calprotectin in 426 lung diseases

Elevated calprotectin and abnormal myeloid cell subsets 434 discriminate severe from mild COVID-19

Late peaks of HMGB1 and sepsis 437 outcome: evidence for synergy with chronic inflammatory disorders

Soluble urokinase plasminogen activator receptor (suPAR) as an 441 early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Receptor recognition by 444 novel coronavirus from Wuhan: an analysis based on decade-long structural 445 studies of SARS coronavirus

Functional assessment of cell entry and receptor 459 usage for SARS-CoV-2 and other lineage B betacoronaviruses

Host-viral infection maps reveal signatures of severe COVID-19 patients

S100A8/S100A9 alarmin activity locally restricts sterile inflammation

Interleukin-1 and related 472 cytokines in the regulation of inflammation and immunity